{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IVC+Pharyngeal+Cancer", "query": { "condition": "Stage IVC Pharyngeal Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IVC+Pharyngeal+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T19:16:06.477Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01552434", "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Neoplasm", "Castleman Disease", "Digestive System Carcinoma", "Erdheim-Chester Disease", "Lip and Oral Cavity Carcinoma", "Lymphangioleiomyomatosis", "Malignant Endocrine Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Male Reproductive System Neoplasm", "Malignant Neoplasm", "Malignant Respiratory Tract Neoplasm", "Malignant Thoracic Neoplasm", "Malignant Urinary System Neoplasm", "Mesothelial Neoplasm", "Metastatic Malignant Neoplasm", "Metastatic Urothelial Carcinoma", "Neurofibromatosis Type 2", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Breast Carcinoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Digestive System Carcinoma", "Recurrent Female Reproductive System Carcinoma", "Recurrent Male Reproductive System Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Pharyngeal Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Malignant Neoplasm", "Soft Tissue Neoplasm", "Stage III Breast Cancer AJCC v7", "Stage III Pharyngeal Cancer", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Pharyngeal Cancer", "Stage IVA Pharyngeal Cancer", "Stage IVB Pharyngeal Cancer", "Stage IVC Pharyngeal Cancer", "Thyroid Gland Neoplasm" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 154, "start_date": "2012-10-16", "completion_date": "2026-05-08", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-25T19:16:06.477Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552434" }, { "nct_id": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Appendix Adenocarcinoma", "Human Papillomavirus-Related Anal Squamous Cell Carcinoma", "Human Papillomavirus-Related Cervical Squamous Cell Carcinoma", "Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis", "Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma", "Neuroendocrine Carcinoma", "Pancreatic Neuroendocrine Tumor", "Recurrent Merkel Cell Carcinoma", "Recurrent Nasopharynx Carcinoma", "Recurrent Peritoneal Malignant Mesothelioma", "Recurrent Pleural Malignant Mesothelioma", "Stage III Merkel Cell Carcinoma AJCC v7", "Stage III Nasopharyngeal Carcinoma AJCC v7", "Stage III Pleural Malignant Mesothelioma AJCC v7", "Stage IV Merkel Cell Carcinoma AJCC v7", "Stage IV Nasopharyngeal Carcinoma AJCC v7", "Stage IV Pleural Malignant Mesothelioma AJCC v7", "Stage IVA Nasopharyngeal Carcinoma AJCC v7", "Stage IVB Nasopharyngeal Carcinoma AJCC v7", "Stage IVC Nasopharyngeal Carcinoma AJCC v7", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2017-03-03", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-06-25T19:16:06.477Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03074513" }, { "nct_id": "NCT02538510", "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Nasopharynx Carcinoma", "Recurrent Salivary Gland Carcinoma", "Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary", "Stage III Major Salivary Gland Carcinoma", "Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage III Nasopharyngeal Carcinoma", "Stage IV Nasopharyngeal Carcinoma", "Stage IVA Major Salivary Gland Carcinoma", "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVB Major Salivary Gland Carcinoma", "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVC Major Salivary Gland Carcinoma", "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2015-10-08", "completion_date": "2023-09-15", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-06-25T19:16:06.477Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538510" }, { "nct_id": "NCT03049358", "title": "Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage 0 Nasopharyngeal Carcinoma", "Stage 0 Paranasal Sinus Cancer", "Stage I Nasopharyngeal Carcinoma", "Stage I Paranasal Sinus Cancer", "Stage II Nasopharyngeal Carcinoma", "Stage II Paranasal Sinus Cancer", "Stage IIA Nasopharyngeal Carcinoma", "Stage IIB Nasopharyngeal Carcinoma", "Stage III Nasopharyngeal Carcinoma", "Stage III Paranasal Sinus Cancer", "Stage IV Nasopharyngeal Carcinoma", "Stage IV Paranasal Sinus Cancer", "Stage IVA Nasopharyngeal Carcinoma", "Stage IVA Paranasal Sinus Cancer", "Stage IVB Nasopharyngeal Carcinoma", "Stage IVB Paranasal Sinus Cancer", "Stage IVC Nasopharyngeal Carcinoma", "Stage IVC Paranasal Sinus Cancer" ], "interventions": [ { "name": "Physiologic Testing", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Sham Intervention", "type": "PROCEDURE" }, { "name": "Therapeutic Procedure", "type": "PROCEDURE" }, { "name": "rose essential oil", "type": "OTHER" }, { "name": "lemon essential oil", "type": "OTHER" }, { "name": "clove essential oil", "type": "OTHER" }, { "name": "eucalyptus essential oil", "type": "OTHER" }, { "name": "canola oil placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 15, "start_date": "2016-12", "completion_date": "2018-10", "has_results": false, "last_update_posted_date": "2019-02-05", "last_synced_at": "2026-06-25T19:16:06.477Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049358" }, { "nct_id": "NCT04541355", "title": "Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Locally Advanced Hypopharyngeal Squamous Cell Carcinoma", "Locally Advanced Laryngeal Squamous Cell Carcinoma", "Locally Advanced Oral Cavity Squamous Cell Carcinoma", "Locally Advanced Oropharyngeal Squamous Cell Carcinoma", "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Lip and Oral Cavity Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVC Hypopharyngeal Carcinoma AJCC v8", "Stage IVC Laryngeal Cancer AJCC v8", "Stage IVC Lip and Oral Cavity Cancer AJCC v8", "Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Hearing Handicap Inventory for Adults - Screening", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Sodium Thiosulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Hyunseok Kang, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-10-14", "completion_date": "2023-05-31", "has_results": true, "last_update_posted_date": "2024-06-28", "last_synced_at": "2026-06-25T19:16:06.477Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04541355" }, { "nct_id": "NCT04162873", "title": "Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Nasal Cavity and Paranasal Sinus Carcinoma", "Oral Cavity Carcinoma", "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Recurrent Hypopharyngeal Carcinoma", "Recurrent Laryngeal Carcinoma", "Recurrent Nasal Cavity and Paranasal Sinus Carcinoma", "Recurrent Oral Cavity Carcinoma", "Recurrent Oropharyngeal Carcinoma", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVC Hypopharyngeal Carcinoma AJCC v8", "Stage IVC Laryngeal Cancer AJCC v8", "Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2019-11-27", "completion_date": "2023-04-26", "has_results": true, "last_update_posted_date": "2025-02-12", "last_synced_at": "2026-06-25T19:16:06.477Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04162873" }, { "nct_id": "NCT01469429", "title": "Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Salivary Gland Squamous Cell Carcinoma", "Stage 0 Hypopharyngeal Cancer", "Stage 0 Laryngeal Cancer", "Stage 0 Lip and Oral Cavity Cancer", "Stage 0 Nasopharyngeal Cancer", "Stage 0 Oropharyngeal Cancer", "Stage 0 Paranasal Sinus and Nasal Cavity Cancer", "Stage I Salivary Gland Cancer", "Stage I Squamous Cell Carcinoma of the Hypopharynx", "Stage I Squamous Cell Carcinoma of the Larynx", "Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage I Squamous Cell Carcinoma of the Nasopharynx", "Stage I Squamous Cell Carcinoma of the Oropharynx", "Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage I Verrucous Carcinoma of the Larynx", "Stage I Verrucous Carcinoma of the Oral Cavity", "Stage II Salivary Gland Cancer", "Stage II Squamous Cell Carcinoma of the Hypopharynx", "Stage II Squamous Cell Carcinoma of the Larynx", "Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage II Squamous Cell Carcinoma of the Nasopharynx", "Stage II Squamous Cell Carcinoma of the Oropharynx", "Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage II Verrucous Carcinoma of the Larynx", "Stage II Verrucous Carcinoma of the Oral Cavity", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Oral Cavity Squamous Cell Carcinoma", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Nasal Cavity and Paranasal Sinus Cancer", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Salivary Gland Cancer", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Oral Cavity Squamous Cell Carcinoma", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Salivary Gland Cancer", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Oral Cavity Squamous Cell Carcinoma", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Paranasal Sinus and Nasal Cavity Squamous Cell Carcinoma", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Tongue Cancer" ], "interventions": [ { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "chemoprevention", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 70, "start_date": "2007-09-04", "completion_date": "2014-09-17", "has_results": false, "last_update_posted_date": "2020-02-20", "last_synced_at": "2026-06-25T19:16:06.477Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01469429" }, { "nct_id": "NCT04788264", "title": "Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Carcinoma", "Hypopharyngeal Carcinoma", "Laryngeal Carcinoma", "Maxillary Sinus Carcinoma", "Oral Cavity Carcinoma", "Oropharyngeal Carcinoma", "Paranasal Sinus Carcinoma", "Sinonasal Carcinoma", "Stage I Laryngeal Cancer AJCC v8", "Stage II Laryngeal Cancer AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVC Laryngeal Cancer AJCC v8", "Lung Carcinoma" ], "interventions": [ { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Consultation", "type": "OTHER" }, { "name": "Exercise Intervention", "type": "OTHER" }, { "name": "Behavioral Intervention", "type": "BEHAVIORAL" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality of Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2021-03-28", "completion_date": "2023-06-29", "has_results": false, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-06-25T19:16:06.477Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04788264" }, { "nct_id": "NCT06997068", "title": "Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Oral Cavity Carcinoma", "Recurrent Oral Cavity Carcinoma", "Stage IVC Lip and Oral Cavity Cancer AJCC v8", "Head and Neck Cancer", "Hypopharynx Cancer", "Oropharynx Cancer", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Metastatic Hypopharyngeal Carcinoma", "Metastatic Laryngeal Carcinoma", "Metastatic Malignant Head and Neck Neoplasm", "Metastatic Oropharyngeal Carcinoma", "Recurrent Hypopharyngeal Carcinoma", "Recurrent Laryngeal Carcinoma", "Recurrent Malignant Head and Neck Neoplasm", "Recurrent Oropharyngeal Carcinoma", "Stage IVC Hypopharyngeal Carcinoma AJCC v8", "Stage IVC Laryngeal Cancer AJCC v8", "Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Imaging Procedure", "type": "PROCEDURE" }, { "name": "Interview", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2025-07-09", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-06-25T19:16:06.477Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06997068" }, { "nct_id": "NCT03422536", "title": "Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Basaloid Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Squamous Cell Carcinoma of Unknown Primary Origin", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IV Oropharyngeal Squamous Cell Carcinoma", "Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IVA Oropharyngeal Squamous Cell Carcinoma", "Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IVB Oropharyngeal Squamous Cell Carcinoma", "Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IVC Oropharyngeal Squamous Cell Carcinoma", "Head and Neck Cancer", "Oropharyngeal Cancer", "HNSCC", "Stage IV Lip and Oral Cavity Squamous Cell Carcinoma" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Ficlatuzumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2017-12-05", "completion_date": "2022-04-05", "has_results": true, "last_update_posted_date": "2024-09-04", "last_synced_at": "2026-06-25T19:16:06.477Z", "location_count": 6, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Tampa, Florida + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03422536" } ] }